{
    "2019-11-26": [
        [
            {
                "time": "2018-01-02",
                "original_text": "This Biotech Broke Out Bullishly — But Couldn't Hold Onto That Gain",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Broke Out",
                        "Bullishly",
                        "Couldn't Hold"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "A new Sickle cell disease drug holds much promise but most sufferers won’t be able to afford it",
                "features": {
                    "keywords": [
                        "Sickle cell",
                        "drug",
                        "promise",
                        "afford"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Global Blood Therapeutics stock is up on sickle cell therapy approval",
                "features": {
                    "keywords": [
                        "Global Blood Therapeutics",
                        "stock",
                        "up",
                        "sickle cell",
                        "therapy",
                        "approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis Securities Investment Ltd -- Moody's affirms Novartis' A1 rating; stable outlook",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Securities",
                        "Investment",
                        "Moody's",
                        "affirms",
                        "A1",
                        "rating",
                        "stable",
                        "outlook"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal",
                "features": {
                    "keywords": [
                        "Drug Stocks",
                        "Ripe",
                        "Takeover",
                        "NVS-MDCO",
                        "Deal"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Top 5 Things to Know in the Market on Tuesday",
                "features": {
                    "keywords": [
                        "Market",
                        "Tuesday"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}